New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medicati... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/28/2024
Locations: Atlantic Health System - Morristown Medical Center, Morristown, New Jersey
Conditions: Melanoma
Twin Block, Pain Medications and Third Molar Extractions
Recruiting
Each year, over 3.5 million, mostly, healthy young adults, have their third molar teeth ('wisdom teeth') removed under sedation and are often given opioid prescriptions for managing their pain. Wisdom molar removal is one of the most common reasons for opioid prescriptions to be given to adolescents. There is a national thrust to reduce both the dose and the duration of such opioid prescriptions because even short-term opioid exposures increase risk for narcotic addiction and misuse. Non-opioid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Rutgers School of Dental Medicine, Newark, New Jersey
Conditions: Acute Pain
Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
Recruiting
Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/25/2024
Locations: Davis Cosmedic Plastic Surgery, Cherry Hill, New Jersey
Conditions: Post Procedural Erythema
Lymphatic System Stimulation in Heart Failure
Recruiting
The goal of this pilot clinical trial is to obtain preliminary data on the effects of lymphatic exercise training in patients with heart failure. The main question\[s\] it aims to answer are: 1. Does performing lymphatic exercise decrease fluid overload symptoms (shortness of breath, lower legs swelling, fatigue), thoracic fluid content, and body fluid level? 2. Does performing lymphatic exercise improve sleep and quality of life (QOL)? Participants with heart failure will be randomly assigned... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/24/2024
Locations: Cooper University Health Care (Cooper), Camden, New Jersey
Conditions: Heart Failure
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: MD Anderson Cancer Center at Cooper, Camden, New Jersey
Conditions: Multiple Myeloma
Reducing Urban Cervical Cancer Disparities
Recruiting
This study uses a hybrid Type 1 effectiveness-implementation trial to operationalize and assess the efficacy of the Health Enhancement Resource System (HERS) intervention. HERS aims to increase patient follow-up after abnormal test results through text message-based barriers counseling for women and supplemental telephone-based Health Coaching for women who miss their appointment.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
10/23/2024
Locations: Rutgers, The State University of New Jersey, New Brunswick, New Jersey
Conditions: Cervical Cancer, Papilloma Viral Infection
Trial of Therapeutic Hypothermia in Patients With ARDS
Recruiting
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/23/2024
Locations: Cooper Health System, Camden, New Jersey
Conditions: Respiratory Distress Syndrome, Adult
First in Human, Dose Escalation Study of AN4005
Recruiting
Open-label, multicenter, phase 1 study to investigate the safety, tolerability, and PK of AN4005 in patients with advanced tumors. This study is a first-in-human, dose escalation study with the objective to establish the MTD and/or RP2D of AN4005. Except for Dose Level 0 (50 mg), a traditional "3 + 3 design" will be utilized for dose finding with dose escalation and/or de-escalation as appropriate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumor, Advanced Lymphoma
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Recruiting
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduc... Read More
Gender:
ALL
Ages:
Between 50 years and 99 years
Trial Updated:
10/21/2024
Locations: The Heart House Haddon Heights, Haddon Heights, New Jersey
Conditions: Heart Failure With Preserved Ejection Fraction
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
Recruiting
The purpose of this study is to test the safety of adding a new drug, durvalumab (also called MEDI4736), to chemoradiation with either FOLFOX/Capeox or carboplatin and paclitaxel, following initial chemotherapy with FOLFOX. The investigators want to find out what effects, good and/or bad, this combination has on the patient and cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey
Conditions: Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Kidney Cancer DNA Registry
Recruiting
This registry will help us develop better methods of: * Preventing these cancers * Diagnosing these cancers * Treating these cancers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: Memorial Sloan Kettering at Basking Ridge (Consent and Follow-up), Basking Ridge, New Jersey
Conditions: Renal Cancer
Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/11/2024
Locations: The Cooper Health System, Camden, New Jersey
Conditions: Down Syndrome, Fetal Aneuploidy